Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
CVRx (CVRX)
NASDAQ:CVRX
Holding CVRX?
Track your performance easily
CVRX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$6.40 - $33.14
Previous Close$13.91
Volume155.19K
Average Volume (3M)315.58K
Market Cap
$337.51M
Enterprise Value$287.51M
Total Cash (Recent Filing)$100.16M
Total Debt (Recent Filing)$50.16M
Price to Earnings (P/E)―
Beta1.99
Next Earnings
Jan 23, 2025EPS Estimate
-$0.39Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.71
Shares Outstanding24,263,663
10 Day Avg. Volume398,301
30 Day Avg. Volume315,577
Standard Deviation0.28
R-Squared0.04
Alpha0.01
Financial Highlights & Ratios
Price to Book (P/B)5.17
Price to Sales (P/S)7.26
Price to Cash Flow (P/CF)-8.20
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue6.08
Enterprise Value/Gross Profit8.70
Enterprise Value/Ebitda-5.13
Forecast
1Y Price Target
$17.20Price Target Upside23.65% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
CVRx News
Bulls Say, Bears Say
Bulls Say
Financial PerformanceCVRx reported Q3’24 revenue of $13.4M (+27% Y/Y), above the Street at $13.2M, with core HF revenue up 30% Y/Y.
Regulatory ApprovalThe American Medical Association has accepted the application for a category I CPT code for Barostim, which could lead to broader utilization and streamlined coverage.
ReimbursementStability in reimbursement will likewise lead to stability in ASP for CVRX.
Bears Say
EarningsEarnings per share fell short of expectations, missing both analyst and market estimates due to increased compensation and headcount costs.
Reimbursement IssuesProposed changes in reimbursement codes could significantly reduce the amount the company receives for its product, affecting profitability.
Revenue ProjectionsThe company has revised its revenue estimates downward, reflecting a less optimistic outlook for the future.
---
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
CVRX FAQ
What was CVRx’s price range in the past 12 months?
CVRx lowest stock price was $6.40 and its highest was $33.13 in the past 12 months.
What is CVRx’s market cap?
Currently, no data Available
When is CVRx’s upcoming earnings report date?
CVRx’s upcoming earnings report date is Jan 23, 2025 which is in 67 days.
How were CVRx’s earnings last quarter?
CVRx released its earnings results on Oct 29, 2024. The company reported -$0.57 earnings per share for the quarter, missing the consensus estimate of -$0.504 by -$0.066.
Is CVRx overvalued?
According to Wall Street analysts CVRx’s price is currently Undervalued.
Does CVRx pay dividends?
CVRx does not currently pay dividends.
What is CVRx’s EPS estimate?
CVRx’s EPS estimate is -$0.39.
How many shares outstanding does CVRx have?
CVRx has 24,263,662 shares outstanding.
What happened to CVRx’s price movement after its last earnings report?
CVRx reported an EPS of -$0.57 in its last earnings report, missing expectations of -$0.504. Following the earnings report the stock price went up 31.006%.
Which hedge fund is a major shareholder of CVRx?
Among the largest hedge funds holding CVRx’s share is Mairs & Power Inc. It holds CVRx’s shares valued at 2M.
---
CVRx Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$17.20 (23.65% Upside)
$17.20 (23.65% Upside)
Blogger Sentiment
Neutral
CVRX Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 74.8K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▲ 1.6%
Last 30 Days ▲ 2.1%
Last 30 Days ▲ 2.1%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-23.73%
12-Months-Change
Fundamentals
Return on Equity
-79.02%
Trailing 12-Months
Asset Growth
19.99%
Trailing 12-Months
Company Description
CVRx
CVRx Inc is a commercial-stage medical device company focused on developing, manufacturing, and commercializing minimally invasive neuromodulation solutions for patients with cardiovascular diseases. Its proprietary platform technology, Barostim, is designed to leverage the power of the brain to address the imbalance of the Autonomic Nervous System, which causes heart failure and other cardiovascular diseases.
---
CVRX Earnings Call
Q3 2024
0:00 / 0:00
---
CVRX Stock 12 Month Forecast
Average Price Target
$17.20
▲(23.65% Upside)
Technical Analysis
Best Analysts Covering CVRX
1 Year
1 Year Success Rate
11/17 ratings generated profit
1 Year Average Return
+30.00%
reiterated a buy rating 19 days ago
Copying Matthew O'Brien's trades and holding each position for 1 Year would result in 64.71% of your transactions generating a profit, with an average return of +30.00% per trade.
---